Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016396 | 0.90 | CYP3A4 (0.57) | CYP3A4GPR119PIK3CAMTORCYP2C9 | |
| SCHEMBL1129044 | 0.89 | CYP3A4 (0.70) | CYP3A4GPR119PIK3CAMTORCYP2C9 | |
| SCHEMBL4352311 | 0.88 | CYP3A4 (0.53) | CYP3A4GPR119ALDH1A1HPGD | |
| SCHEMBL4357368 | 0.85 | CYP3A4 (0.54) | CYP3A4GPR119PIK3CAMTORCYP2C9 | |
| SCHEMBL2019853 | 0.85 | CYP3A4 (0.61) | CYP3A4GPR119PIK3CAMTORCYP2C9 | |
| SCHEMBL1128724 | 0.85 | CYP3A4 (0.61) | CYP3A4GPR119PIK3CAMTORCYP2C9 | |
| SCHEMBL12574275 | 0.84 | GPR119 (0.58) | CYP3A4GPR119ALDH1A1HPGD | |
| SCHEMBL10139985 | 0.83 | GPR119 (0.55) | GPR119CYP2C9ALDH1A1HPGD | |
| SCHEMBL1128465 | 0.83 | CYP3A4 (0.59) | CYP3A4GPR119PIK3CAMTORCYP2C9 | |
| SCHEMBL1128407 | 0.83 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | claimed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, GCKR, GID4 | CYP3A4 789/4885GPR119 1/4885PIK3CA 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.